Publications scientifiques Bordet

Autophagy inhibition improves sensitivity to the multi-kinase inhibitor regorafenib in preclinical mouse colon tumoroids.

Agostini G, Leprovots M, Jeandriens J, Lefort A, Libert F, Sclafani F, Langer I, Hendlisz A, Garcia MI

Autophagy inhibition improves sensitivity to the multi-kinase inhibitor regorafenib in preclinical mouse colon tumoroids.

Agostini G, Leprovots M, Jeandriens J, Lefort A, Libert F, Sclafani F, Langer I, Hendlisz A, Garcia MI

Autophagy inhibition improves sensitivity to the multi-kinase inhibitor regorafenib in preclinical mouse colon tumoroids.

Corrigendum to \"Histopathological Insights into Metastatic Breast Cancer Gained From Rapid Autopsies\" [Laboratory Investigation 105(2025) 104202].

Zels G, Pabba A, De Schepper M, Geukens T, Van Baelen K, Maetens M, Mahdami A, Leduc S, Isnaldi E, Nguyen HL, Bachir I, Van Cauwenberge J, Borremans K, Weynand B, Biganzoli E, Neven P, Wildiers H, Van Den Bogaert W, Richard F, Desmedt C, Floris G

Corrigendum to \"Histopathological Insights into Metastatic Breast Cancer Gained From Rapid Autopsies\" [Laboratory Investigation 105(2025) 104202].

Prospective comparison between geriatric assessment and clinical evaluation in 200 newly diagnosed older adults with multiple myeloma.

Raddoux J, Kenis C, Vanhellemont A, Meers S, Mineur P, Vekemans MC, Wu KL, Caers J, Van Eygen K, Kentos A, Depaus J, Put N, Van De Velde A, Claes G, Vlummens P, Maertens V, Meuleman N, Broek IV, Vaes M, Fostier K, Demuynck H, Delforge M

Prospective comparison between geriatric assessment and clinical evaluation in 200 newly diagnosed older adults with multiple myeloma.

The prognostic value of PTEN expression in localized prostate cancer.

Bellouti A, Sirtaine N, Roumeguere T, Peltier A, Diamand R

The prognostic value of PTEN expression in localized prostate cancer.

Bellouti A, Sirtaine N, Roumeguere T, Peltier A, Diamand R

The prognostic value of PTEN expression in localized prostate cancer.

The SCARLET trial: a prospective phase II study of somatostatin receptor imaging for potential radiotheranostic application in patients with relapsing and refractory multiple myeloma.

Delbart W, Karfis I, Vercruyssen M, De Wind R, Meuleman N, Wimana Z, Flamen P, Woff E

The SCARLET trial: a prospective phase II study of somatostatin receptor imaging for potential radiotheranostic application in patients with relapsing and refractory multiple myeloma.

Delbart W, Karfis I, Vercruyssen M, De Wind R, Meuleman N, Wimana Z, Flamen P, Woff E

The SCARLET trial: a prospective phase II study of somatostatin receptor imaging for potential radiotheranostic application in patients with relapsing and refractory multiple myeloma.

Delbart W, Karfis I, Vercruyssen M, De Wind R, Meuleman N, Wimana Z, Flamen P, Woff E

The SCARLET trial: a prospective phase II study of somatostatin receptor imaging for potential radiotheranostic application in patients with relapsing and refractory multiple myeloma.

Hôpital Erasme

Consultez toutes les publications scientifiques d'Erasmus

Publications scientifiques d'Erasmus

Hôpital pédiatrique Reine Fabiola

Consultez toutes les publications scientifiques de l'Hôpital pédiatrique Reine Fabiola

Publications scientifiques de l'Hôpital pour enfants Reine Fabiola

Institut Jules Bordet

Consultez toutes les publications scientifiques de Jules Bordet

Publications scientifiques de Jules Bordet

Publications scientifiques Bordet